Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology
Summary
The solutions – spanning genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, epigenetics, and data analytics software – will enable researchers to derive breakthrough insights around the drivers of disease. Stephen Kingsmore, MD, DSc, president and CEO of Rady Childrens Institute for Genomic Medicine, will share his experience with constellation mapped read technology and the potential impact for comprehensive, rapid WGS that can enable earlier diagnosis of genetic and rare diseases. The solution is expected to launch by the end of 2025 with three new kit formats that are compatible with 10,000, 100,000, and 1 million cells per sample, facilitating targeted studies with 100 guide RNA (gRNA) sequences to full genome-scale discovery with over 10,000 gRNAs per experiment. Early access customer data will be presented by Bekim Sadikovic, PhD, director of the Molecular Genetics Laboratory at London Health Sciences Centre Research Institute, in a concurrent session on Tuesday, February 25, 9:10–9:30 p.m. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand.